Taysha Gene Therapies, Inc. (TSHA) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TSHA Revenue Growth
TSHA Revenue Analysis (2019–2025)
As of May 8, 2026, Taysha Gene Therapies, Inc. (TSHA) generated trailing twelve-month (TTM) revenue of $7.5 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, TSHA's historical revenue data shows a 3-year CAGR of +57.5%. The company achieved its highest annual revenue of $15.5 million in 2023.
When compared to Healthcare sector peers including SRPT (-2.2% YoY), RARE (+13.3% YoY), and FOLD (+20.0% YoY), TSHA has underperformed the peer group in terms of revenue growth. Compare TSHA vs SRPT →
TSHA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TSHACurrent | $7M | -100.0% | - | -1130.6% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% |
TSHA Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $9.8M | +17.3% | $8.6M | 88.3% | $-110,498,000 | -1130.6% |
| 2024 | $8.3M | -46.1% | $8.3M | 100.0% | $-91,459,000 | -1097.6% |
| 2023 | $15.5M | +517.5% | $15.5M | 100.0% | $-72,439,000 | -468.8% |
| 2022 | $2.5M | - | $15K | 0.6% | $-126,027,000 | -5037.1% |
| 2021 | $0 | - | $0 | - | $-173,267,000 | - |
| 2020 | $0 | - | $-9,000 | - | $-43,002,000 | - |
| 2019 | $0 | - | $0 | - | $-1,115,000 | - |
See TSHA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TSHA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TSHA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTSHA — Frequently Asked Questions
Quick answers to the most common questions about buying TSHA stock.
Is TSHA's revenue growth accelerating or slowing?
TSHA revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $7M. This reverses the prior growth trend.
What is TSHA's long-term revenue growth rate?
Taysha Gene Therapies, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is TSHA's revenue distributed by segment?
TSHA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.